Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture? Available to Purchase

Classic Hodgkin Lymphoma (cHL) is highly curable with risk-adapted first-line treatment. Due to exceptional efficacy, anti-programmed cell death protein 1 antibodies (aPD1) are increasingly incorporated into first-line treatment. The short- and long-term immune-related adverse event (irAE) burden in this setting, however, is insufficiently understood. Herein, we review the currently available evidence on feasibility and safety of aPD1 first-line cHL treatment. A more harmonized and complete reporting is critical to enable a detailed understanding and comprehensive assessment of aPD1-related morbidity.